- Location
wet AMD
"-
Bayer HealthCare Has Submitted VEGF Trap-Eye for Regulatory Approval in Japan
Dec 5, 2013Bayer HealthCare has submitted VEGF Trap-Eye (aflibercept solution for injection) for regulatory approval in Japan to treat patients with myopic choroidal neovascularization (myopic CNV), one of the most common causes of eye disease. In ...
-
Bayer and Regeneron Pharmaceuticals Are Collaborating on The Global Development of Eylea
Nov 26, 2013Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Bayer HealthCare's Eylea (aflibercept, solution for intravitreal injection) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO). In ...
-
Oraya Therapeutics Announced Initial Three-Year Safety Follow-up Data From Its Study
Nov 19, 2013Oraya Therapeutics announced that initial three-year safety follow-up data from its INTREPID study of Oraya Therapy stereotactic radiotherapy for the treatment of wet age-related macular degeneration (AMD) were presented for the first time ...
Tags: Oraya Therapeutics, Medicine
-
Bayer Has Received Approval From Health Canada for Eylea for Treatment of Patients
Nov 15, 2013Bayer has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD). AMD, a progressive eye disease that ...
Tags: Wet AMD Patients, Bayer
-
Allegro Ophthalmics Has Received Approval From FDA for IND Application
Oct 11, 2013Allegro Ophthalmics has received approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to commence two Phase II clinical studies of integrin peptide therapy ALG-1001. The new trials, ...
Tags: Eye Disease Patients
-
European Commission Has Approved Regeneron Pharmaceuticals's Eylea Injection
Sep 2, 2013The European Commission has approved Regeneron Pharmaceuticals's Eylea (aflibercept) injection for the treatment of visual impairment caused by macular edema secondary to central retinal vein occlusion (CRVO). Eylea is a recombinant ...
Tags: fusion protein, Eylea
-
Lpath Has Won a US patent
May 31, 2013Lpath has won a US patent covering methods of using monoclonal antibodies for the treatment and prevention of ocular conditions, including wet age-related macular degeneration (AMD). The patent includes the use of monoclonal antibodies, ...
-
A New Study Has Looked at Whether an Individual Is Likely to Develop AMD
Feb 19, 2013A new study has looked at how certain gene variants may predict whether an individual is likely to develop age-related macular degeneration (AMD). This eye disease affects over nine million Americans, but it has been found that certain ...
-
EC Has Approved Aflibercept Solution for Injection
Nov 29, 2012The European Commission (EC) has approved Bayer HealthCare's EYLEA (aflibercept solution for injection) at a recommended dose of 2 mg for the treatment of wet age-related macular degeneration (wet AMD). Formulated as an iso-osmotic ...
Tags: European Commission, Bayer, Aflibercept Solution, EYLEA
-
Allergan and Molecular Partners Have Expanded Their Existing Relationship
Nov 29, 2012Allergan and Molecular Partners have expanded their existing relationship by entering into two separate agreements to discover, develop and commercialize proprietary therapeutic DARPin products to treat ophthalmic diseases. The first ...
-
Eylea Injection Be Approved by Japan
Nov 27, 2012Regeneron Pharmaceuticals has received Japanese Ministry of Health,Labour and Welfare(MHLW)approval for its Eylea(aflibercept)injection to treat patients with neovascular age-related macular degeneration(wet AMD)symptoms. Regeneron chief ...
Tags: Regeneron Pharmaceuticals, Eylea Injection, wet AMD, George Yancopoulos
-
Genentech Has Acquired Clearance for Its Lucentis 0.3 Mg From The US FDA
Aug 13, 2012Genentech, a member of Roche Group, has obtained clearance for its Lucentis 0.3 mg (ranibizumab injection) from the US Food and Drug Administration (FDA). Lucentis 0.3 mg is a recombinant humanized monoclonal antibody fragment (lacking an ...
Tags: Genentech, Lucentis 0.3 mg, Medicine, Injection
-
Bayer Yakuhin Signs a Agreement with Santen Pharmaceutical for Eylea Injection in Japan
Jul 29, 2012Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin has signed a co-promotion agreement with Santen Pharmaceutical for Eylea (aflibercept) injection in Japan. Eylea is approved for sale in the US and Australia for the treatment of ...
